Cumberland Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products designed to improve quality of care and address unmet medical needs. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose (lactulose) for Oral Solution, a prescription laxative, Vaprisol (conivaptan) Injection, for the treatment of hyponatremia and Omeclamox-Pak for the treatment of H. pylori and duodenal ulcer disease, and Ethyol (amifostine) for Injection, for the treatment of oncology patients. The Company also owns rights to ifetroban and are developing Hepatoren (ifetroban) Injection for the treatment of Hepatorenal Syndrome, Boxaban (ifetroban) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, VasculanTM (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban, for the treatment of portal hypertension.

Cumberland Pharmaceuticals was founded in 1999 and is headquartered in Nashville, US

Cumberland Pharmaceuticals has an office in Nashville

Nashville, US (HQ)

950 2525 West End Ave

Cumberland Pharmaceuticals's revenue was reported to be $9.6 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 9.6 m |

## Gross profit (Q1, 2017) | 8.3 m |

## Gross profit margin (Q1, 2017), % | 86% |

## Net income (Q1, 2017) | (1.3 m) |

## EBIT (Q1, 2017) | (657.8 k) |

## Market capitalization (15-Aug-2017) | 105.5 m |

## Cash (31-Mar-2017) | 35 m |

Cumberland Pharmaceuticals's current market capitalization is $105.5 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 32 m | 36.9 m | 33.5 m | 33 m |

## Revenue growth, % | 15% | (9%) | (1%) | |

## Cost of goods sold | 5.4 m | 5.1 m | 5 m | 6 m |

## Gross profit | 26.6 m | 31.8 m | 28.6 m | 27.1 m |

## Gross profit Margin, % | 83% | 86% | 85% | 82% |

## Sales and marketing expense | 14.4 m | 14.9 m | ||

## R&D expense | 5.6 m | 3.4 m | ||

## General and administrative expense | 9.5 m | 8.4 m | ||

## Operating expense total | 35.8 m | 33.3 m | 32.4 m | 34.5 m |

## EBIT | (3.8 m) | 3.6 m | 1.1 m | (1.4 m) |

## EBIT margin, % | (12%) | 10% | 3% | (4%) |

## Interest expense | 103.4 k | 67.1 k | 73.9 k | 106.4 k |

## Interest income | 230.3 k | 251.4 k | 209.2 k | 204.7 k |

## Pre tax profit | (3.7 m) | 3.7 m | 1.2 m | (1.3 m) |

## Income tax expense | (1.5 m) | 1.4 m | (575.8 k) | 330.9 k |

## Net Income | (2.2 m) | 2.4 m | 671.1 k | (1 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 9.8 m | 9.7 m | 8.7 m | 8.9 m | 7.9 m | 7.7 m | 7.4 m | 8.8 m | 9.6 m |

## Cost of goods sold | 1.3 m | 1.3 m | 1.2 m | 1.2 m | 980.2 k | 1.2 m | 1.2 m | 2 m | 1.4 m |

## Gross profit | 8.5 m | 8.4 m | 7.5 m | 7.7 m | 6.9 m | 6.5 m | 6.3 m | 6.8 m | 8.3 m |

## Gross profit Margin, % | 87% | 86% | 87% | 86% | 88% | 84% | 84% | 78% | 86% |

## R&D expense | 861.2 k | 934.8 k | 1.9 m | 828.1 k | 757.4 k | 706.5 k | 678.8 k | 644.7 k | 898.4 k |

## General and administrative expense | 2.1 m | 2.2 m | 1.6 m | 2.2 m | 1.8 m | 2.1 m | 1.9 m | 1.9 m | 2.1 m |

## Operating expense total | 3 m | 3.1 m | 3.5 m | 3 m | 2.6 m | 2.8 m | 2.6 m | 2.5 m | 3 m |

## EBIT | 1.2 m | 989 k | 4.1 k | 673.9 k | 270.9 k | (500.6 k) | (105.3 k) | 130.1 k | (657.8 k) |

## EBIT margin, % | 12% | 10% | 0% | 8% | 3% | (6%) | (1%) | 1% | (7%) |

## Interest expense | (12.3 k) | (26.9 k) | (15.6 k) | (18.5 k) | (19.8 k) | (20.4 k) | (28.2 k) | (29.1 k) | (31.7 k) |

## Interest income | 29.5 k | 108 k | 56.4 k | 57.8 k | 64.1 k | 77.1 k | 31.5 k | 51.6 k | 52.5 k |

## Pre tax profit | 1.2 m | 1.1 m | 45 k | 713.3 k | 315.1 k | (443.9 k) | (102.1 k) | 152.7 k | (637 k) |

## Income tax expense | (523.3 k) | (341 k) | (18.5 k) | (319 k) | (193.4 k) | 175.3 k | 41.1 k | (57.2 k) | (656.6 k) |

## Net Income | 709.5 k | 729.2 k | 26.5 k | 394.3 k | 121.7 k | (268.6 k) | (60.9 k) | 95.5 k | (1.3 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 40.9 m | 39.9 m | 38.2 m | 34.5 m |

## Inventories | 5.7 m | 5.6 m | 4.3 m | 5.4 m |

## Current Assets | 68.7 m | 70.8 m | 67.1 m | 65.5 m |

## PP&E | 880.6 k | 651 k | 536.5 k | 464.5 k |

## Total Assets | 87.6 m | 95.4 m | 91.9 m | 93.4 m |

## Accounts Payable | 2 m | 3.2 m | 2.9 m | 8 m |

## Current Liabilities | 7.5 m | 13.7 m | 12.4 m | 14.8 m |

## Total Liabilities | 20.3 m | |||

## Retained Earnings | 16.4 m | 18.8 m | 19.5 m | 18.6 m |

## Total Equity | 79.3 m | 80.8 m | 76.8 m | 73.1 m |

## Financial Leverage | 1.1 x | 1.2 x | 1.2 x | 1.3 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 39.1 m | 39.6 m | 39 m | 38.9 m | 38.3 m | 36.4 m | 35.8 m | 35.5 m | 35 m |

## Inventories | 7 m | 6.1 m | 4.6 m | 4.8 m | 4.2 m | 4.1 m | 4.9 m | 5 m | 5.6 m |

## Current Assets | 70.6 m | 70.1 m | 67.5 m | 68.2 m | 67.7 m | 64.9 m | 64 m | 67 m | 63.5 m |

## PP&E | 726.9 k | 731.1 k | 685.2 k | 568.8 k | 541.8 k | 558.2 k | 505.7 k | 482.6 k | 538.4 k |

## Total Assets | 93.5 m | 93.9 m | 92.2 m | 92.9 m | 92.1 m | 89.2 m | 87.9 m | 91.1 m | 91.9 m |

## Accounts Payable | 4.2 m | 3.2 m | 3.4 m | 4.1 m | 4.1 m | 4.1 m | 3.7 m | 6.7 m | 7.3 m |

## Current Liabilities | 11.9 m | 12.2 m | 11.9 m | 11.5 m | 11.9 m | 11.1 m | 8.9 m | 11.7 m | 14.1 m |

## Retained Earnings | 17.4 m | 18.1 m | 18.9 m | 19.3 m | 19.4 m | 19.3 m | 19.2 m | 19.4 m | 18.4 m |

## Total Equity | 80.7 m | 80.9 m | 79.3 m | 78.7 m | 77.5 m | 75.3 m | 74.4 m | 74.4 m | 72.2 m |

## Financial Leverage | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.3 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (2.2 m) | 2.4 m | 671.1 k | (1 m) |

## Depreciation and Amortization | 1.3 m | 2 m | 2.2 m | 2.4 m |

## Accounts Receivable | 1.5 m | (974.3 k) | (572.4 k) | (1.3 m) |

## Inventories | 495.5 k | 1.5 m | 1.3 m | (1.1 m) |

## Accounts Payable | 1.5 m | 191.9 k | ||

## Cash From Operating Activities | 746.1 k | 6.7 m | 5.9 m | 569.5 k |

## Purchases of PP&E | (97.4 k) | (163.3 k) | (143 k) | (130.9 k) |

## Cash From Investing Activities | (5.1 m) | (6 m) | (2.3 m) | (3.1 m) |

## Cash From Financing Activities | (9.2 m) | (1.7 m) | (5.2 m) | (1.1 m) |

## Interest Paid | 79.3 k | 28.4 k | 27.4 k | 21.9 k |

## Income Taxes Paid | (129.5 k) | 17.1 k | 52.2 k | (8.4 k) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 709.5 k | 729.2 k | 26.5 k | 394.3 k | 121.7 k | (268.6 k) | (60.9 k) | 95.5 k | (1.3 m) |

## Inventories | 7 m | 6.1 m | 4.6 m | 4.8 m | 4.2 m | 4.1 m | 4.9 m | 5 m | |

## Accounts Payable | 4.2 m | 3.2 m | 3.4 m | 4.1 m | 4.1 m | 4.1 m | 3.7 m | 6.7 m | 7.3 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 117.5 k |

## Financial Leverage | 1.3 x |